Why the study?
Does a statin-nicotinic acid-aspirin mini-polypill improve compliance and outcomes in patients with combined hyperlipidaemia?
Does a statin-nicotinic acid-aspirin mini-polypill improve compliance and outcomes in patients with combined hyperlipidaemia?
A mini-polypill combining a statin, nicotinic acid, and aspirin is proposed as a promising strategy to improve compliance, manage combined hyperlipidaemia, and reduce side effects in high-risk patients.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for a mini-polypill in combined hyperlipidaemia; prospective trials needed before any practice change.
This review considers the treatment for combined hyperlipidaemia (CH) with a combination formulation of three drugs: a statin, nicotinic acid (NA) and aspirin--a mini-polypill. CH is a highly atherogenic dyslipidaemia manifested either as familial combined hyperlipidaemia or dyslipidaemia related to the metabolic syndrome or Type 2 diabetes mellitus. These types of dyslipidaemia are highly prevalent in the general population. Statin plus extended-release NA is a promising treatment option for the normalisation of these atherogenic lipid alterations, regression of atherosclerosis, as well as for primary or secondary prevention of cardiovascular disease (CVD) events. The addition of aspirin might prove a useful adjunct that might reduce the cutaneous side effects of NA while also acting as an antiplatelet agent in high-CVD-risk patients. However, the effective dose of aspirin may need to be at least 160 mg/day. This triple combination might improve patient compliance when compared with the three drugs administered separately.
No takes yet. Share an insight, caveat, or question.
Athyros et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: